News
Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...
The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...
The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot ...
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...
Zacks Investment Research on MSN2d
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...
The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.
The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback